Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 6162 | 1457 | 47.3 | 94% |
Classes in level above (level 2) |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | 4 1BB | Author keyword | 129 | 76% | 6% | 91 |
| 2 | OX40 | Author keyword | 62 | 57% | 5% | 73 |
| 3 | CD137 | Author keyword | 53 | 59% | 4% | 60 |
| 4 | CD70 | Author keyword | 46 | 59% | 4% | 51 |
| 5 | 4 1BB LIGAND | Author keyword | 45 | 90% | 1% | 19 |
| 6 | 4 1BBL | Author keyword | 44 | 74% | 2% | 32 |
| 7 | IMMUNOMODULAT | Address | 28 | 32% | 5% | 74 |
| 8 | GITR | Author keyword | 26 | 49% | 3% | 38 |
| 9 | CD27 | Author keyword | 24 | 34% | 4% | 58 |
| 10 | OX40L | Author keyword | 21 | 57% | 2% | 25 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | 4 1BB | 129 | 76% | 6% | 91 | Search 4+1BB | Search 4+1BB |
| 2 | OX40 | 62 | 57% | 5% | 73 | Search OX40 | Search OX40 |
| 3 | CD137 | 53 | 59% | 4% | 60 | Search CD137 | Search CD137 |
| 4 | CD70 | 46 | 59% | 4% | 51 | Search CD70 | Search CD70 |
| 5 | 4 1BB LIGAND | 45 | 90% | 1% | 19 | Search 4+1BB+LIGAND | Search 4+1BB+LIGAND |
| 6 | 4 1BBL | 44 | 74% | 2% | 32 | Search 4+1BBL | Search 4+1BBL |
| 7 | GITR | 26 | 49% | 3% | 38 | Search GITR | Search GITR |
| 8 | CD27 | 24 | 34% | 4% | 58 | Search CD27 | Search CD27 |
| 9 | OX40L | 21 | 57% | 2% | 25 | Search OX40L | Search OX40L |
| 10 | GITRL | 21 | 75% | 1% | 15 | Search GITRL | Search GITRL |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | 4 1BB LIGAND | 156 | 70% | 9% | 128 |
| 2 | ANTI 4 1BB MONOCLONAL ANTIBODIES | 93 | 91% | 3% | 39 |
| 3 | 4 1BB | 79 | 62% | 6% | 81 |
| 4 | HUMAN 4 1BB | 76 | 100% | 2% | 24 |
| 5 | OX40 OX40 LIGAND INTERACTION | 46 | 82% | 2% | 27 |
| 6 | OX40 LIGAND | 46 | 37% | 7% | 99 |
| 7 | CD137 ILA 4 1BB | 45 | 94% | 1% | 16 |
| 8 | CD27 CD70 INTERACTIONS | 44 | 65% | 3% | 42 |
| 9 | INDUCED TNF RECEPTOR | 41 | 41% | 5% | 79 |
| 10 | GITR | 40 | 67% | 2% | 36 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| The role of TNF superfamily members in T-cell function and diseases | 2009 | 269 | 132 | 77% |
| Control of Immunity by the TNFR-Related Molecule OX40 (CD134) | 2010 | 118 | 134 | 79% |
| Tnf/tnfr family members in costimulation of T cell responses | 2005 | 618 | 306 | 63% |
| Co-stimulatory members of the TNFR family: Keys to effective T-cell immunity? | 2003 | 501 | 129 | 69% |
| Immunotherapy of Cancer with 4-1BB | 2012 | 42 | 70 | 81% |
| Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies | 2010 | 85 | 35 | 66% |
| Immune regulation by 4-1BB and 4-1BBL: complexities and challenges | 2009 | 97 | 183 | 62% |
| The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy | 2013 | 22 | 61 | 67% |
| CD137 ligand, a member of the tumor necrosis factor family, regulates immune responses via reverse signal transduction | 2011 | 30 | 74 | 84% |
| Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology | 2009 | 81 | 139 | 63% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | IMMUNOMODULAT | 28 | 32% | 5.1% | 74 |
| 2 | RD CANC THER EUT | 21 | 73% | 1.1% | 16 |
| 3 | EARLE A CHILES | 13 | 24% | 3.3% | 48 |
| 4 | SECT CLIN IMMUNOL ALLERGY RHEUMATOL | 10 | 50% | 1.0% | 14 |
| 5 | ROBERT W FRANZ CANC | 8 | 23% | 2.0% | 29 |
| 6 | CELL IMMUNOBIOL | 5 | 39% | 0.8% | 11 |
| 7 | SEZ FARMACOL TOSSICOL CHEMIOTER IA | 5 | 54% | 0.5% | 7 |
| 8 | PROGRAM IMMUNOL BIOMED | 4 | 75% | 0.2% | 3 |
| 9 | CELL IMMUNOBIOL RD CANC THER EUT | 3 | 100% | 0.2% | 3 |
| 10 | IMMUNODULAT | 3 | 100% | 0.2% | 3 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000106971 | SOLUBLE CD30//SCD30//CD30 |
| 2 | 0.0000101724 | ICOS//B7RP 1//ICOSL |
| 3 | 0.0000078134 | CD28//CD80//B7 |
| 4 | 0.0000072194 | TAK1//TRAF4//TRAF5 |
| 5 | 0.0000065790 | B7 H4//PD 1//PD L1 |
| 6 | 0.0000065280 | INTERDISCIPLINARY PROGRAM IMMUNOL//INTEGRATED IMMUNOL VACCINE//T CELL COMPETITION |
| 7 | 0.0000064720 | CD40//CD40 LIGAND//CD40L |
| 8 | 0.0000058524 | DCR3//DECOY RECEPTOR 3//TL1A |
| 9 | 0.0000055730 | PHARMACEUT PROTE//PRE LIGAND BINDING ASSEMBLY DOMAIN PLAD//TUMOR NECROSIS FACTOR RECEPTOR TNFR |
| 10 | 0.0000053225 | LYMPHOTOXIN//LT BETA R//BTLA |